How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 9, 2007, Pages 641-650

  Schlumberger, Martin ^a,b   Ricard, Marcel ^b   De Pouvourville, Gérard ^c   Pacini, Furio ^d,e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c ESSEC BUSINESS SCHOOL   (France)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Ablation; Follow up; Recombinant human TsH; Thyroglobulin; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE; IODINE 131; LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN;

COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG UPTAKE; ECHOGRAPHY; FATIGUE; FOLLICULAR CARCINOMA; HUMAN; HYPOTHYROIDISM; NAUSEA; PAPILLARY CARCINOMA; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SINGLE DRUG DOSE; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

ALGORITHMS; HUMANS; IODINE RADIOISOTOPES; POSTOPERATIVE CARE; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TREATMENT OUTCOME;

EID: 34548083106     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0594     Document Type: Review

References (43)

1. Schlumberger M et al. (2007) Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3: 260-269
2. Cooper DS et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 1-33
3. Pacini F et al. (2006) European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 154: 787-803
4. Dow KH et al. (1997) Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7: 613-619
5. Duntas LH and Biondi B (2007) Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 156: 13-19
6. Busnardo B et al. (1983) Different rates of serum thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine. J Endocrinol Invest 6: 35-40
7. Wondisford FE et al. (1988) Cloning of the human thyrotropin ?-subunit gene and transient expression of biologically active human thyrotropin after gene transfection. Mol Endocrinol 2: 32-39
8. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 91: 506-510
9. Torres MS et al. (2001) Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 86: 1660-1664
10. Meier CA et al. (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78: 188-196
11. Pacini F et al. (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91: 926-932
12. Hänscheid H et al. (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47: 648-654
13. 131I. J Nucl Med 44: 1065-1068
14. Potzi C et al. (2006) Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 65: 519-523
15. Luster M et al. (2005) Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmaco economic comparison to recombinant thyrotropin administration. Thyroid 15: 1147-1155
16. Schroeder PR et al. (2006) A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal. J Clin Endocrinol Metab 91: 878-884
17. Cohen O et al. (2004) Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrinol 150: 285-290
18. Haugen BR et al. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877-3885
19. Eustatia-Rutten CFA et al. (2004) Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured metaanalysis. Clin Endocrinol (Oxf) 61: 61-74
20. Cailleux AF et al. (2000) Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab 85: 175-178
21. Pacini F et al. (2002) Diagnostic 131-iodine wholebody scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87: 1499-1501
22. Frasoldati A et al. (2003) Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97: 90-96
23. Torlontano M et al. (2004) Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89: 3402-3407
24. Pacini F et al. (2003) rhTSH-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88: 3668-3673
25. Baudin E et al. (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up following thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88: 1107-1111
26. 131I activities versus untreated patients. J Clin Endocrinol Metab 86: 4092-4097
27. 131I therapy for elevated thyroglobulin levels. Thyroid 7: 273-276
28. Leboulleux S et al. (2007) The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 3: 112-121
29. Schlumberger M et al. (2007) Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 92: 2487-2495
30. Smallridge RC et al. (2007) Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92: 82-87
31. Robbins RJ at al. (2002) A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 43: 1482-1488
32. Barbaro D et al. (2003) Radioiodine treatment with 30 mCi after recombinant human TSH stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88: 4110-4115
33. Pilli T et al. (2007) A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab [doi:10.1210/jc.2007-0225]
34. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87: 4063-4068
35. Luster M et al. (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12: 49-64
36. 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 81: 1724-1725
37. Durante C et al. (2006) Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892-2899
38. Vargas GE et al. (1999) Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab 84: 3867-3871
39. Braga M et al. (2001) Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 86: 5148-5151
40. Blamey S et al. (2005) Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. ANZ J Surg 75: 10-20
41. Borget I et al. (2007) Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen® and Thyroid hormone withdrawal. Eur J Endocrinol 156: 531-538
42. De Pouvourville G et al. (2007) Comparison of four strategies of follow-up in thyroid cancer patients: a cost-utility analysis. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology: 2007 June 1-5, Chicago, IL
43. Mernagh P et al. (2006) Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 155: 405-414